Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Gains from Sales and Divestitures (2016 - 2020)

Historic Gains from Sales and Divestitures for Celldex Therapeutics (CLDX) over the last 9 years, with Q4 2020 value amounting to $1110.0.

  • Celldex Therapeutics' Gains from Sales and Divestitures fell 5000.0% to $1110.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $1110.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $1110.0 for FY2020, which is 5000.0% down from last year.
  • Celldex Therapeutics' Gains from Sales and Divestitures amounted to $1110.0 in Q4 2020, which was down 5000.0% from $2220.0 recorded in Q4 2019.
  • Over the past 5 years, Celldex Therapeutics' Gains from Sales and Divestitures peaked at $19500.0 during Q4 2016, and registered a low of $1110.0 during Q4 2020.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $2449.0 (2018), whereas its average is $8388.8.
  • In the last 5 years, Celldex Therapeutics' Gains from Sales and Divestitures tumbled by 8530.45% in 2018 and then crashed by 935.08% in 2019.
  • Over the past 5 years, Celldex Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $19500.0 in 2016, then dropped by 14.54% to $16665.0 in 2017, then crashed by 85.3% to $2449.0 in 2018, then fell by 9.35% to $2220.0 in 2019, then tumbled by 50.0% to $1110.0 in 2020.
  • Its Gains from Sales and Divestitures stands at $1110.0 for Q4 2020, versus $2220.0 for Q4 2019 and $2449.0 for Q4 2018.